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ABSTRACT 
Poor outcome hebephrenic schizophrenia patients are clinically challenging. In this 
report, we demonstrate the usefulness of pimozide add-on thereapy to ongoing 
clozapine regime in a case who poorly reponded to clozapine, ECT and adequate trials 
with at least two conventional antipsychotics. 
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DISSCUSSION 
INTRODUCTION 
Antipsychotics in high doses arc not 
necessarily successful in therapy resistance 
schizophrenia (Mardcr, 2000) whereas 
switching to another antipsychotic of a 
different class could be a better alternative. 
In patients who arc refractory even to 
clozapine, coadministration of another 
antipsychotic, i.c, risperidone, loxapinc, 
sulpiride, olanzapine or pimozide may 
produce favourable results (Stubb et al., 
2000). 
In this report, we highlight the successful 
use of pimozide to augment ongoing 
clozapine treatment. 
CASE 
Mrs. K, a 28-year lady, presented with a history 
of abnormal behaviour, which started insidiously 
and remained progressive for 14 years. She was 
found to have inappropriate laughter, muttering, 
odd gestures, social withdrawal and wandering 
tendency. In addition, she had disruptive behaviour 
and occasional urinary incontinence. She spoke 
irrelevantly and had poor personal care and social 
interest. On occasions, she would express paranoid 
ideas and hallucinatory behaviour. 
On first contact, her mental status examination 
revealed poor grooming, inadequate eye contact, 
frequent grimacing, loosening of association and 
inappropriate affect. At this point, she was diagnosed 
as hebephrenic schizophrenia. 
In the past, Mrs. K was treated with haloperidol 
25 mg/day and chlorpromazine upto 700 mg/day 
without any response. About 7 years back, she was 
treated with a course of ECTs, which produced a 
minimal response, whereupon she was married. 
However, her clinical condition deteriorated withon 
2 months. She was treated with olanzapine 40 mg/ 
day, 8 months back, for 12 weeks, but there was 
no response. 1-ater, she was given another course 
of 12 ECTs with a marginal, ill-sustained response. 
After the diagnosis and baseline investigations, 
the patient was switched over to clozapine 
monotherapy. The dose was gradually increased to 
450 mg/day, with weekly monitoring of blood 
counts. Even at this dose, she did not show any 
change in her behavior. However the dose could 
not be further increased because of excessive 
sedation. Pimozide was then added and gradually 
increased to 8 mg/day, along with trihexyphenidyl 
4 mg/day. ECG was done at regular, frequent 
intervals. After addtion of pimozide, Mrs. K showed 
marked improvement in her behavior, particularly 
in affect, personal care, irrevalent talk, and grimacing. 
However, she continued to exhibit withdrawn 
behavior and had to be prompted to carry out her 
activities. This case was followed up for 6 months 
without any relapse of psychotic symptoms. 
The term augmentation in this case refers 
to the use of two agents to achieve an 
enhanced antipsychotic response. Recent 
review on augmentation of clozapine (Stubb 
et al, 2000) did not mention about treatment 
with ECT, duration of illness, type of 
schizophrenia, type of antipsychotic drug 
that the patient was receiving, and presence 
of comorbidity. Friedman et al (1997) have 
earlier reported on the augmentation of 
clozapine with pimozide, in 5 schizophrenic 
patients. 
As pimozide prolongs the QT interval, 
one should anticipate an additive effect on 
QT interval if coadministered with other 
drugs having similar pharmacokinetics 
(Kastrup, 1999). Hence, we had to frequently 
monitor ECG. 
The reason for enhanced clinical efficacy 
of pimozide augmentation to clozapine in 
schizophrenia is difficult to explain. Pimozide 
may have increased the level of serum 
clozapine (Friedman, 1997). 
Although atypical antipsychotics are now 
available, of treatment resistant patients 
continue to challenge the clinician. For these 
patients, pimozide add on could offer a 
realistic augmentation strategy. 
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